Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Sasanlimab, Pfizer's subcutaneous PD-1 inhibitor, targets BCG-unresponsive NMIBC. Explore the JAVELIN Bladder RACE program, PDUFA status, and what analysts need to know.
Article | Rapport Map the 2026 EV thermal runaway prevention landscape: AI early warning, BTMS, fire suppression, and key patent trends from 2017–2026. Research from PatSnap.
Article | Rapport How R&D teams use structured analogy methods—TRIZ, biomimicry, design-by-analogy—to find breakthrough solutions from unrelated engineering domains.
Article | Rapport How machine learning is transforming materials discovery in 2026: property prediction, synthesis optimization, and the key platforms powering R&D breakthroughs.
Article | Rapport Tezepelumab (Tezspire) is advancing into COPD clinical trials. Explore the TSLP biology, AstraZeneca/Amgen strategy, and what Phase III expansion means for obstructive lung disease.
Article | Rapport A 2026 technology landscape of biochar soil carbon sequestration: patent gaps, key research clusters, geographic hotspots, and strategic IP implications for PyCCS.
Article | Rapport Analyse 70+ patents on CMC turbine blade technology: SiC-SiC architectures, root attachment IP, top assignees, and five emerging directions shaping propulsion in 2026.
Article | Rapport Savolitinib targets MET-driven papillary renal cell carcinoma in Phase III trials. Explore the AstraZeneca/Hutchmed registration strategy, mechanism, and IP landscape.
Article | Rapport How AI is reshaping the way engineers identify and evaluate cross-industry technology transfer opportunities — from patent mining to innovation scouting.
Article | Rapport Explore the 2026 LCA landscape for cobalt, lithium, and nickel battery supply chains — methodologies, environmental impact modeling, and patent intelligence.
Article | Rapport How engineers use patent citation mapping to identify seminal inventions in emerging tech. Covers forward & backward citation analysis, network methods, and R&D strategy.
Article | Rapport Gefurulimab and AstraZeneca's C5 complement inhibitor enter Phase II/III in myasthenia gravis. How do they compare to efgartigimod and ravulizumab?
Article | Rapport Explore the 2026 nanocellulose composite materials landscape for packaging and structural applications — patent trends, key players, and innovation intelligence.
Article | Rapport AEMWE patent and literature landscape 2026: membrane chemistry, non-PGM catalysts, scale-up milestones, and strategic IP white space for green hydrogen.
Article | Rapport Giredestrant (GDC-9545) enters Phase III in early HR+ breast cancer via Roche's evERA trial. Analyse the oral SERD competitive landscape: imlunestrant, camizestrant, elacestrant & more.